US Pharma MarketingCelcuity aims for broad FDA approval after positive breast cancer readout
Celcuity Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial.
Executives shared details on Tuesday at this year's American ...
Source: Endpoints News